By Amit Kakkar, Managing Editor, EmiratesReporter.com
Disclaimer: This article is based on publicly available research, regulatory announcements, media reports, and expert opinions available at the time of publication. It is intended solely for general information and reading purposes and should not be considered medical advice, diagnosis, treatment, or a recommendation to use any medication. No claims regarding the effectiveness, safety, or suitability of Wegovy or any other treatment are being made by the publisher. Individuals living with obesity, overweight, diabetes, or any other health condition should consult a qualified healthcare professional before making any medical or treatment-related decisions. Readers should rely on the advice of their physicians and relevant health authorities regarding the benefits, risks, side effects, and suitability of any medication.
Dubai, UAE- The arrival of the oral Wegovy pill in the UAE is more than just a pharmaceutical launch. It is a sign of how obesity treatment is changing around the world. For years, weight-loss medicines have mostly been associated with injections. Now, a ‘once-daily tablet’ is here to make obesity treatment easier, more accessible, and less intimidating for many people. The UAE has become the first country outside the United States to launch the oral version of Wegovy, placing the nation at the forefront of a major shift in obesity care.
Wegovy is manufactured by Novo Nordisk and the drug works by mimicking a natural hormone that helps regulate appetite and food intake. In simple terms, it helps people feel full for longer periods, reducing hunger and calorie consumption.
The approval was granted by the Emirates Drug Establishment after reviewing clinical data showing that the medicine supports weight reduction, long-term weight management, and can help lower the risk of serious cardiovascular events in people who are overweight or obese and at risk of heart disease. The regulator emphasized that the medicine should be used together with a healthy diet and increased physical activity rather than as a standalone solution.
One of the biggest reasons doctors are welcoming the pill is convenience. Many patients who qualify for obesity treatment are reluctant to take weekly injections. A tablet removes that psychological barrier. Doctors in the UAE have previously described the oral option as an important step because some patients are more likely to begin and continue treatment when it comes in pill form.
The science behind the medicine is also attracting attention. Clinical studies have shown significant weight reduction among patients using oral semaglutide. Trial data cited by regulators and researchers demonstrated meaningful weight loss compared with placebo treatments, making it one of the most effective oral obesity medicines developed so far. Reuters and European regulators have highlighted results showing average weight-loss outcomes exceeding 15% in some studies.
Novo Nordisk says the UAE was chosen for this launch because of strong patient demand, growing healthcare infrastructure, telehealth capabilities, and the readiness of healthcare professionals to manage obesity as a chronic disease. Emil Kongshoj Larsen, the company’s head of international operations, described the UAE launch as an important milestone in expanding access to innovative obesity care worldwide.
Yet the excitement should not overshadow an important reality. Obesity is not simply about appearance. It is linked to diabetes, heart disease, high blood pressure, sleep disorders, joint problems, and other chronic conditions. The UAE, like many countries, faces rising obesity rates and the associated healthcare burden. A medicine can help, but it cannot replace healthy habits. Long-term success still depends on nutrition, exercise, medical supervision, and lifestyle changes as also suggested by medical experts.
Another important question is accessibility. Wegovy is not intended for everyone who wants to lose a few kilograms before a holiday. It is generally prescribed for adults living with obesity or for overweight individuals who have obesity-related health conditions. The medicine requires medical assessment and ongoing monitoring by healthcare professionals. Patients should not self-medicate or seek the drug without proper medical advice.
There is also growing competition in this market. The arrival of multiple oral treatments could increase patient choice and accelerate innovation in obesity care. Analysts believe the global obesity-drug market could exceed $100 billion annually over the coming decade, highlighting how significant this medical field has become.
The real story is not that a new pill has arrived. The real story is that obesity is increasingly being treated as a serious chronic disease rather than a lifestyle issue. The UAE’s decision to approve and launch oral Wegovy sends a message that modern obesity care is moving toward earlier intervention, wider access, and more patient-friendly treatment options.
Whether this pill becomes a game changer will depend not only on its clinical success but also on how responsibly it is prescribed and how seriously society continues to address the root causes of obesity.
